Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness

Live updates

1. 34m ago

   FDA orders blindness warning on GLP-1 drugs including Ozempic, Wegovy, Zepbound

   The U.S. Food and Drug Administration has ordered manufacturers of popular GLP-1 diabetes and weight-loss drugs to add warnings about a rare eye condition that can cause permanent vision loss. The condition, non-arteritic anterior ischemic optic neuropathy (NAION), has been reported in patients taking semaglutide and tirzepatide products. Affected brands include Ozempic, Wegovy, Rybelsus, Zepbound, and Mounjaro. The FDA says the risk is rare but serious, and the new label language must reflect the potential for irreversible blindness.

   Why it matters

   GLP-1 receptor agonists have become blockbuster treatments for type 2 diabetes and obesity, with millions of prescriptions written annually. The NAION risk emerged from post-marketing surveillance and observational studies, not clinical trials. Regulators in Europe and the U.K. are also reviewing similar signals. The warning adds a new dimension to benefit-risk discussions for patients and prescribers, especially those with existing optic nerve vulnerabilities.

   What is confirmed

   • FDA ordered manufacturers to add warnings about non-arteritic anterior ischemic optic neuropathy (NAION) to GLP-1 drug labels.
   • Affected drugs include semaglutide products Ozempic, Wegovy, Rybelsus and tirzepatide products Zepbound, Mounjaro.
   • NAION is a rare condition that can cause sudden, permanent vision loss.
   • The risk was identified through post-marketing adverse event reports and observational data.

   Still unconfirmed

   • The absolute incidence rate of NAION in GLP-1 users remains undefined.
   • European regulators may follow with similar label changes.

   What to watch next

   • FDA publication of exact label language and implementation timeline
   • European Medicines Agency and MHRA regulatory decisions on NAION warnings
   • Large-scale epidemiological studies quantifying NAION incidence in GLP-1 users vs. controls
   Sources used for this update (14)

   1. www.yahoo.com — Yahoo
   2. CNN — US FDA orders new eye risk warnings for Ozempic, Zepbound
   3. CBS News — GLP-1 drugs, popular for weight loss, get FDA warning of rare vision-loss side effect
   4. CNBC — FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
   5. Fox Business — FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
   6. BBC — Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
   7. The Washington Post — The FDA has a new warning about GLP-1s and vision loss. Should you worry?
   8. NPR — FDA warns GLP-1s could increase risk of vision loss : Here & Now Anytime
   9. Medical Xpress — Rare eye condition prompts new FDA warning on popular GLP-1 drugs
   10. The Guardian — FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
   11. STAT — GLP-1s are given an FDA warning for rare eye condition risk
   12. AZ Family — FDA requires blindness warning label on GLP-1 drugs
   confidence 92%